Orchid gets US FDA approval for Cefpodixime Proxetil

Chennai, Nov 17: Orchid Chemicals and Pharmaceuticals Limited announced that it has received approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Cefpodoxime Proxetil tablets.

The product was available in two dosage strengths such as 100 mg and 200 mg, a company release here today said.

Cefpodoxime Proxetil was third generation cephalosporin antibiotic, which had a broad spectrum activity against organisms causing infectious diseases.

With limited generic competition in this product Orchid hopes to garner a sizeable market share and revenues in the US market, the release added.

UNI